- Title
- Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial
- Creator
- Acheson, Liam S.; Ezard, Nadine; Shoptaw, Steve; Siefried, Krista J.; Lintzeris, Nicholas; Dunlop, Adrian; Brett, Jonathan; Rodgers, Craig; Gill, Anthony; Christmass, Michael; McKetin, Rebecca; Farrell, Michael
- Relation
- Drug and Alcohol Dependence Vol. 241, Issue 1 December 2022, no. 109692
- Publisher Link
- http://dx.doi.org/10.1016/j.drugalcdep.2022.109692
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2022
- Description
- Background: There is no effective treatment for methamphetamine withdrawal. This study aimed to determine the feasibility and safety of a tapering dose of lisdexamfetamine for the treatment of acute methamphetamine (MA) withdrawal. Methods: Open-label, single-arm pilot study, in an inpatient drug and alcohol withdrawal unit assessing a tapering dose of oral lisdexamfetamine dimesylate commencing at 250 mg once daily, reducing by 50 mg per day to 50 mg on Day 5. Measures were assessed daily (days 0–7) with 21-day telephone follow-up. Feasibility was measured by the time taken to enrol the sample. Safety was the number of adverse events (AEs) by system organ class. Retention was the proportion to complete treatment. Other measures included the Treatment Satisfaction Questionnaire for Medication (TSQM), the Amphetamine Withdrawal Questionnaire and craving (Visual Analogue Scale). Results: Ten adults seeking inpatient treatment for MA withdrawal (9 male, median age 37.1 years [IQR 31.7–41.9]), diagnosed with MA use disorder were recruited. The trial was open for 126 days; enroling one participant every 12.6 days. Eight of ten participants completed treatment (Day 5). Two participants left treatment early. There were no treatment-related serious adverse events (SAEs). Forty-seven AEs were recorded, 17 (36%) of which were potentially causally related, all graded as mild severity. Acceptability of the study drug by TSQM was rated at 100% at treatment completion. Withdrawal severity and craving reduced through the admission. Conclusion: A tapering dose regimen of lisdexamfetamine was safe and feasible for the treatment of acute methamphetamine withdrawal in an inpatient setting.
- Subject
- methamphetamine; lisdexamfetamine; withdrawal; safety; clinical trial; pharmacotherapy; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1489170
- Identifier
- uon:52634
- Identifier
- ISSN:0376-8716
- Language
- eng
- Reviewed
- Hits: 4503
- Visitors: 4471
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|